ALN-VSP02

DRUG2 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Solid Tumors

Phase 1

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

CompletedNCT00882180

Alnylam PharmaceuticalsSolid Tumors

Start: 2009-03-31End: 2011-08-31Updated: 2011-08-24

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

CompletedNCT01158079

Alnylam PharmaceuticalsSolid Tumors

Start: 2010-07-31End: 2012-09-30Updated: 2012-10-12